...
机译:二甲双胍的添加减轻了单纯用药的初发精神分裂症患者中奥氮平诱导的体重增加:一项双盲,安慰剂对照的研究
Ren-RongWu, M.D.Jing-Ping Zhao, M.D.Xiao-Feng Guo, M.D.Yi-Qun He, M.D.Mao-Sheng Fang, M.D.Wen-Bin Guo, M.D.Jin-Dong Chen, M.D.Le-Hua Li, M.D.Received Jan. 12, 2007, revisions received April 13, June 12, July 24, and Aug. 17, 2007, accepted Aug. 20, 2007 (doi: 10.1176/ appi.ajp.2007.07010079). From the Institute of Mental Health of the Second Xiangya Hospital, Central South University, Changsha, China. Address correspondence and reprint requests to Dr. Zhao, Institute of Mental Health of the second Xiangya Hospital, Central South University, 139 Renmin Middle Road, Changsha 410011, Hunan, China, zhaojingpinghunan@yahoo.com.cn (e-mail).The authors report no competing interests.Supported by National Key Technologies R&D Program in the 10th 5-year-plan grant 2004BA720A22 (Dr. Zhao) from the Ministry of Science and Technology of the People's Republic of China.,;
机译:在未经药物治疗的首发精神分裂症患者中,二甲双胍的添加减轻了奥氮平诱导的体重增加:一项双盲,安慰剂对照研究。
机译:二甲双胍治疗首发精神分裂症妇女的抗精神病药性闭经和体重增加:一项双盲,随机,安慰剂对照研究
机译:二甲双胍衰减肝脏脂肪含量:从精神分裂症患者发现奥拉扎滨诱导的体重增加
机译:使用扩散加权成像识别初发性精神分裂症患者的生物标志物
机译:鱼油(二十碳五烯酸和二十二碳六烯酸)对急性肺损伤患者的肺和全身炎症的II期,随机,双盲,安慰剂对照试验。
机译:二甲双胍减轻肝脏脂肪含量:从奥氮平诱导的体重增加的精神分裂症患者中发现
机译:二甲双胍衰减肝脏脂肪含量:从精神分裂症患者发现奥拉扎滨诱导的体重增加